Skip to main content
SpringerLink
Log in

Afatinib/cetuximab/erlotinib

Acneiform eruption: 33 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kikuchi K, et al. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. Journal of Dermatology 46: 18-25, No. 1, Jan 2019. Available from: URL: http://doi.org/10.1111/1346-8138.14691 - Japan

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/cetuximab/erlotinib. Reactions Weekly 1739, 17 (2019). https://doi.org/10.1007/s40278-019-57657-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-57657-8

Search

Navigation